The new drug for obstructive hypertrophic cardiomyopathy (oHCM), 'Camzyos,' has entered the last stage for reimbursement listing.

Sources said that the Ministry of Health and Welfare (MOHW) ordered the National Health Insurance Service (NHIS) to initiate a drug price negotiation for Bristol Myers Squibb Korea's Camzyos (mavacamten), a treatment for obstructive hypertrophic cardiomyopathy (oHCM).

The company encountered several hurdles with Camzyos during the review process; for instance, the drug received a re-assessment status during the Health Insurance Review and Assessment Service (HIRA) review. Therefore, all eyes are on whether Camzyos will be approved for the reimbursement list. <